Target intelligence / Profile preview

TatD DNase domain containing 3 (TATDN3)

Target
TATDN3
Molecular classification
Enzyme, Exonuclease, DNA repair enzyme, Apurinic/apyrimidinic endonuclease (in vitro activity[2]), TIM-barrel fold protein (structural classification[1])
01

Overview

TatD DNase domain containing 3 is a magnesium-dependent exonuclease that preferentially digests single-stranded DNA and RNA from the 3′- to 5′-end, with some apurinic/apyrimidinic endonuclease activity observed in vitro[1][2]. Structurally, it contains a TIM-barrel motif, which is common in enzymes with diverse catalytic activities[1]. Functionally, TATDN3 is implicated in DNA repair processes, including nucleotide excision and double-strand break repair, and has additional suggested roles in apoptotic DNA fragmentation[1]. Its activity is essential for maintaining genome integrity, particularly in response to oxidative DNA damage. The protein is evolutionarily conserved across species, underscoring its fundamental biological importance[1][3]. Specific disease associations, drug interactions, and clinical utility remain under investigation, with most current data supporting its general relevance to DNA repair and apoptosis[1][2][3][4].

Other names
Deoxyribonuclease TATDN3DNA-(apurinic or apyrimidinic site) endonuclease TATDN3Putative deoxyribonuclease TATDN3TATDN3
02

Mechanism of action

Not established for specific drugs. Hypothetically, inhibitors would block exonuclease activity and interfere with DNA repair; activators could enhance genome stability.

03

Biological functions

DNA repair (processing single-stranded DNA ends, nucleotide excision, double-strand break repair[1])DNA fragmentation during apoptosis[1]Maintenance of genome integrity[3]
04

Disease associations

Cancer (suggested involvement in apoptosis and DNA repair pathways, possibly affecting cancer susceptibility and progression[1])Other (potential roles in diseases linked to DNA repair defects, though direct links to specific diseases are not established)
05

Safety considerations

No specific concerns reported[1][2][3][4]. General risks include potential genome instability if TATDN3 is inhibited, possibly increasing cancer risk or sensitivity to DNA-damaging agents.

Beyond the preview

Go deeper on TatD DNase domain containing 3 (TATDN3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TatD DNase domain containing 3 (TATDN3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call